Advertisement
Advertisement
ANIK
Anika Therapeutics Inc
13.47
USDSponsored
-1.10
-7.55%
Nov 10, 15:59 UTC -5
Closed
After-Market
13.48
+0.01
+0.11%
Anika Therapeutics Inc (ANIK) Earnings
ANIK Earnings Reports
Positive Surprise Ratio
ANIK beat 26 of 44 last estimates.
59%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$30.59M
/$0.10
Implied change from Q3 26 (Revenue/ EPS)
--
/-600.00%
Implied change from Q4 25 (Revenue/ EPS)
-0.07%
/+400.00%
Anika Therapeutics Inc earnings per share and revenue
On Nov 06, 2026, ANIK reported earnings of -0.02 USD per share (EPS) for Q3 26, missing the estimate of 0.06 USD, resulting in a -132.68% surprise. Revenue reached 30.59 million, compared to an expected 30.02 million, with a 1.90% difference. The market reacted with a -24.73% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 4 analysts forecast an EPS of 0.10 USD, with revenue projected to reach 30.59 million USD, implying an decrease of -600.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Anika Therapeutics Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Anika Therapeutics Inc reported EPS of -$0.02, missing estimates by -132.68%, and revenue of $30.59M, 1.9% above expectations.
How did the market react to Anika Therapeutics Inc's Q3 2026 earnings?
The stock price moved down -24.73%, changed from $19.33 before the earnings release to $14.55 the day after.
When is Anika Therapeutics Inc expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Anika Therapeutics Inc's next earnings report?
Based on 4
analysts, Anika Therapeutics Inc is expected to report EPS of $0.10 and revenue of $30.59M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.